Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13618897 | 0.93 | NPC1 (0.61) | NPC1POLBKMT2AMEN1UTS2R | |
| SCHEMBL13618890 | 0.85 | NPC1 (0.42) | NPC1POLBKMT2AMEN1UTS2R | |
| SCHEMBL13618885 | 0.82 | HSD17B1 (0.48) | POLBKMT2AMEN1UTS2RALDH1A1 | |
| SCHEMBL13618893 | 0.82 | NPC1 (0.42) | NPC1POLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL13618876 | 0.82 | HSD17B1 (0.49) | POLBKMT2AMEN1UTS2RALDH1A1 | |
| SCHEMBL13618891 | 0.77 | NPC1 (0.35) | NPC1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL13618896 | 0.77 | NPC1 (0.49) | NPC1POLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL13618886 | 0.75 | HSD17B1 (0.50) | NPC1KMT2AMEN1UTS2RALDH1A1 | |
| SCHEMBL13618899 | 0.75 | HSD17B1 (0.48) | NPC1POLBKMT2AMEN1UTS2R | |
| SCHEMBL13618878 | 0.74 | HSD17B1 (0.52) | NPC1KMT2AMEN1UTS2RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286765-A1 | Therapeutic Agents | GRIA1, GRIN1, GLRA1 | NPC1 151/4885POLB 4418/4885KMT2A 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.